348 related articles for article (PubMed ID: 7636196)
1. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
2. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
Penna C; Dean PA; Nelson H
Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104
[TBL] [Abstract][Full Text] [Related]
3. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application.
Chapoval AI; Nelson H; Thibault C; Penna C; Dean P
J Hematother; 1995 Dec; 4(6):571-7. PubMed ID: 8846018
[TBL] [Abstract][Full Text] [Related]
5. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
Tutt A; Stevenson GT; Glennie MJ
J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of in vitro tumor-infiltrating lymphocyte cytotoxicity by heteroconjugated antibodies.
Reid I; Lundy J; Donohue JH
J Immunol; 1992 Apr; 148(8):2630-5. PubMed ID: 1532818
[TBL] [Abstract][Full Text] [Related]
7. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
Thibault C; Nelson H; Chapoval AI
Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
[TBL] [Abstract][Full Text] [Related]
9. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
[TBL] [Abstract][Full Text] [Related]
11. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
12. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
13. Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TCR alpha/beta x anti-CD2) F(ab')2 antibody.
Tutt AL; Reid R; Wilkins BS; Glennie MJ
J Immunol; 1995 Sep; 155(6):2960-71. PubMed ID: 7673714
[TBL] [Abstract][Full Text] [Related]
14. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
Molema G; Tervaert JW; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
Br J Cancer; 2000 Jan; 82(2):472-9. PubMed ID: 10646907
[TBL] [Abstract][Full Text] [Related]
15. Target cell-induced T cell activation with bi- and trispecific antibody fragments.
Jung G; Freimann U; Von Marschall Z; Reisfeld RA; Wilmanns W
Eur J Immunol; 1991 Oct; 21(10):2431-5. PubMed ID: 1655465
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
Kahn M; Sugawara H; McGowan P; Okuno K; Nagoya S; Hellström KE; Hellström I; Greenberg P
J Immunol; 1991 May; 146(9):3235-41. PubMed ID: 1707934
[TBL] [Abstract][Full Text] [Related]
17. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
18. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
Nitta T; Yagita H; Azuma T; Sato K; Okumura K
Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460
[TBL] [Abstract][Full Text] [Related]
19. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M
J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188
[TBL] [Abstract][Full Text] [Related]
20. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
